214450.KQ
214450.KQ
KR7214450009
PharmaResearch
Loading chart...

Company Profile

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.

Related stocks

141080.KQ
141080.KQ • South Korea
LCB
73,300 KRW
2.02B USD 1Y -51.9%
226950.KQ
226950.KQ • South Korea
OliX
117,300 KRW
1.84B USD 1Y +27.9%
298380.KQ
298380.KQ • South Korea
ABL Bio
48,000 KRW
2.01B USD 1Y -49.9%
145020.KQ
145020.KQ • South Korea
Hugel
182,800 KRW
1.47B USD 1Y -36%
302440.KS
302440.KS • South Korea
SKBS
36,750 KRW
2.15B USD 1Y -22.6%
0009K0.KQ
0009K0.KQ • South Korea
Aimed Bio
24,250 KRW
1.16B USD
326030.KS
326030.KS • South Korea
SKBP
72,700 KRW
4.25B USD 1Y -30.4%
0126Z0.KS
0126Z0.KS • South Korea
SAMSUNG EPIS HOLDINGS
340,500 KRW
6.32B USD

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
53.3% p.a.
Max Drawdown (5Y)
-63.6%
Sharpe Ratio (5Y)
0.51
Beta Factor
0.47
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Elevated Short-Term Volatility: 3Y volatility (61.0%) is noticeably higher than the 5Y average (53.3%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (53.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -63.6% in the extended horizon.
ende